Vertex Pharmaceuticals Inc. closed 18.83% below its 52-week high of $519.88, which the company achieved on November 8th.

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind the ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

Houston-based Vertex Energy Inc . (OTC Pink:OTC:VTNRQ), a petroleum refining company with annual revenues of $3.2 billion, has received confirmation from the U.S. Bankruptcy Court for the Southern ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks that will make you rich in 2025. Jurrien Timmer, Director of ...